Prevalence and Risk Factors of Substance Use Disorder in Inflammatory Bowel Disease

Heather Carney,* Ruth Ann Marrie, MD, PhD,1,4 James M. Bolton, MD, PhD,5,6 Scott B. Patten, MD, PhD,6 Lesley A. Graff, PhD,1 Charles N. Bernstein, MD,4 Kaarina Kowalec, PhD,*,**,*; for the CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease

Background: Substance use disorders (SUDs) impose a substantial individual and societal burden; however, the prevalence and associated factors in persons with inflammatory bowel disease (IBD) are largely unknown. We evaluated the prevalence and risk factors of SUD in an IBD cohort.

Methods: Inflammatory bowel disease participants (n = 247) were recruited via hospital- and community-based gastroenterology clinics, a population-based IBD research registry, and primary care providers as part of a larger cohort study of psychiatric comorbidity in immune-mediated inflammatory diseases. The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders IV was administered to participants to identify lifetime SUD, anxiety disorder, and major depressive disorder. Additional questionnaires regarding participants’ sociodemographic and clinical characteristics were also completed. We examined demographic and clinical factors associated with lifetime SUD using unadjusted and adjusted logistic regression modeling.

Results: Forty-one (16.6%) IBD participants met the criteria for a lifetime diagnosis of an SUD. Factors associated with elevated odds of SUD were ever smoking (adjusted odds ratio [aOR], 2.96; 95% confidence interval [CI], 1.17–7.50), male sex (aOR, 2.44; 95% CI, 1.11–5.36), lifetime anxiety disorder (aOR, 2.41; 95% CI, 1.08–5.37), and higher pain impact (aOR, 1.08; 95% CI, 1.01–1.16).

Conclusions: One in six persons with IBD experienced an SUD, suggesting that clinicians should maintain high index of suspicion regarding possible SUD, and inquiries about substance use should be a part of care for IBD patients, particularly for men, smokers, and patients with anxiety disorders and pain.

Key Words: inflammatory bowel disease, substance use disorders, SCID

INTRODUCTION

Psychiatric disorders are strongly associated with inflammatory bowel disease (IBD). Persons with IBD have over twice the odds of generalized anxiety disorder (AD) and major depressive disorder (MDD) compared with the general population.1,3 However, there has been minimal investigation of substance use disorder (SUD) in those with IBD. Existing research regarding SUD in those with IBD has been limited to

Conflicts of interest: RAM receives research funding from CIHR, the MS Society of Canada, the MS Scientific Research Foundation, CMSC, National MS Society, Crohn’s and Colitis Canada, Research Manitoba, the Arthritis Society, and the Waugh Family Chair in Multiple Sclerosis. CNB has consulted for Abbvie Canada, Janssen Canada, Pfizer Canada, Shire Canada, Takeda Canada, and Mylan pharmaceuticals; has received unrestricted educational grants from Abbvie Canada, Janssen Canada, Shire Canada, and Takeda Canada; has been on the speaker's bureau of Abbvie Canada, Janssen Canada, Takeda Canada and Medtronic Canada; has done contract work with Abbvie, Celgene, Janssen, Boehringer Ingelheim, and Roche. KK has consulted with Emerald Lake Safety Ltd. (2017–2018); has received speaker honoraria from Biogen/Fraser Health MS Clinic (2018); and has received research funding from the European Research Council, Government of Canada, National MS Society, and The Consortium of MS Centers. HC, JMB, SBP and LAG declare no conflicts.

Address correspondence to: Kaarina Kowalec, 750 McDermot Ave, Winnipeg MB R3N 0T5, Canada. E-mail: kaarina.kowalec@umanitoba.ca

© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

For commercial re-use, please contact journals.permissions@oup.com
doi: 10.1093/ibd/izaa014
Published online 6 February 2020
either specific subpopulations with IBD, including pregnant and postpartum women, or has investigated self-reported substance use but not specialist- or interviewer-diagnosed SUD. A review of studies examining alcohol use in IBD found a similar prevalence of alcohol consumption in those with IBD compared with the general population, and most studies identified an association between alcohol consumption and a worsening of IBD symptoms.

Substance use disorder may complicate the management of IBD. Comorbid SUD and chronic conditions are associated with higher rates of hospitalization than chronic conditions alone, and the presence of an SUD may interfere with adherence to treatment of the chronic condition and self-care behaviors. The high prevalence of psychiatric disorders in IBD and the association between AD, mood disorders, and SUD in the general population suggest that persons with IBD may have an relatively high prevalence of SUD. The prevalence and predictors of SUD in those with IBD are unknown. Therefore, we aimed to evaluate the frequency of and risk factors for SUD in those with IBD.

MATERIAL AND METHODS

Study Design

This study used data from the enrollment visit of a cohort study investigating psychiatric comorbidities in immune-mediated inflammatory diseases, as described elsewhere. Briefly, between 2014 and 2016, the study recruited 247 individuals with IBD for a 3-year longitudinal study from various sites within the Canadian province of Manitoba.

Study Population

Participants with IBD, including Crohn’s disease (CD) and ulcerative colitis (UC), were recruited via multiple routes to ensure broad representativeness, including hospital- and community-based gastroenterology clinics, a population-based IBD research registry, and primary care providers. Inflammatory bowel disease was confirmed by medical records review or through the treating physician. Participants were 18 years of age or older and able to provide informed consent.

Procedures

After providing consent, participants completed self-report questionnaires during their initial study visit that captured sociodemographic and clinical information. The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV (SCID) was administered in person or over the phone by a trained interviewer. As described elsewhere, interviewers included nurses, graduate students, and research coordinators who were trained by a registered clinical health psychologist, with regular review of fidelity to the interview method.

Measures

Sociodemographic and clinical characteristic self-report questionnaires provided the following characteristics: age, sex, race, marital status, household income, highest level of education, and smoking history. Race was categorized as white or nonwhite, due to a limited number of nonwhite participants. Annual household income was grouped as “< $50,000,” “≥ $50,000,” or “decline to answer” to ensure reasonable cell sizes. Highest level of education was dichotomized as “high school or below” and “above high school.” Marital status was classified as “single” (including never married, divorced, widowed, separated) or “married/common-law.” Participants reported current and past smoking behaviors; participants who reported having in their lifetime smoked ≥100 cigarettes were categorized as “ever smokers.” Self-reported, physician-diagnosed physical comorbidities (including cardiovascular diseases, diabetes mellitus, kidney disease, and cancers, among others) were recorded using a validated comorbidity questionnaire. Pain impact was recorded using the Modified Medical Outcomes Study Pain Effects Scale, a valid, reliable tool derived from the Pain Effects Scale that includes a 6-item assessment of the effects of pain, defined as any unpleasant sensory symptom on mood and activities during the previous 4 weeks. Total scores range from 6 to 30, with higher scores indicating greater impact of pain. Though additional measures of different pain dimensions would have been useful, only a single measure was used to reduce participant burden.

IBD-specific Characteristics

Participants with IBD were subtyped as either ulcerative colitis or Crohn’s disease. Age of IBD onset was characterized using the Montreal classification, which groups age of IBD onset as younger than 17, 17 to 40, and over 40 years of age. Inflammatory bowel disease activity was assessed using validated clinical indices: for UC, using the Powell-Tuck Index, and for CD, using the Harvey-Bradshaw Index; scores ≥5 on both scales reflected symptomatically active disease.

Mental Disorders

Mental disorders were identified according to the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria, the prevailing diagnostic criteria at the time the study was designed, based on the participant’s SCID. Substance use disorders were defined by meeting diagnostic criteria for current or lifetime SUD and categorized by DSM-IV diagnoses: alcohol abuse, alcohol dependence, drug abuse, and drug dependence. The following drugs were included in this definition: sedatives, hypnotics, anxiolytics, cannabis, stimulants, opioids, cocaine, hallucinogens, and other drugs (eg, steroids, solvents). Tobacco use was not included. We also summarized self-reported lifetime alcohol and substance use that did not meet DSM-IV diagnostic criteria, which we report here as “ever substance use.”
Participants were classified as having an AD if they met diagnostic criteria for any current or lifetime AD. Anxiety classifications followed DSM-IV disorders: panic disorder, generalized anxiety disorder, agoraphobia without history of panic disorder, specific phobia, social phobia, AD due to a general medical condition, substance-induced AD, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD). Participants were categorized as having MDD if they met diagnostic criteria for current or lifetime MDD. Both current and lifetime AD and MDD were considered to allow for a greater understanding of the lifetime relationship between SUD and AD and/or MDD. Population-based studies have shown that the incidence and prevalence of bipolar disorder are higher in the IBD population than the non-IBD population, in the context of a low base rate overall.\(^{18,19}\) However, we did not include bipolar disorder due to the small number of affected participants in our cohort (n = 4, 1.6%).

**Statistical Analysis**

Participant characteristics were summarized for the full IBD cohort and then stratified by the presence or absence of SUD. We compared participants with and without SUD using descriptive statistics (\(\chi^2\) tests and Student t tests). The frequency and characteristics of current and lifetime SUD were summarized in the full IBD cohort.

We used binary logistic regression models to determine the association between various patient characteristics and SUD, with associations reported as unadjusted and adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs). The following factors were considered in the multivariable model for an association with SUD in IBD: sex, age, marital status, number of physical comorbidities, pain impact, smoking history, IBD subtype, SCID-diagnosed MDD, and SCID-diagnosed AD. The covariates were chosen either based on previously established associations with SUD (male, age, marital status, physical comorbidities, pain impact, smoking history, IBD subtype, SCID-diagnosed MDD, and SCID-diagnosed AD). The covariates were chosen either based on previously established associations with SUD (male, age, marital status, physical comorbidities, pain impact, smoking history, IBD subtype, SCID-diagnosed MDD, and SCID-diagnosed AD). The covariates were chosen either based on previously established associations with SUD (male, age, marital status, physical comorbidities, pain impact, smoking history, IBD subtype, SCID-diagnosed MDD, and SCID-diagnosed AD).

Multivariable logistic regression analysis subsequently revealed ever smoking (adjusted OR [aOR], 2.96; 95% CI, 1.17–7.50), male sex (aOR, 2.44; 95% CI, 1.11–5.36), lifetime AD (aOR, 2.41; 95% CI, 1.08–5.37), and higher pain impact (aOR, 1.08; 95% CI, 1.01–1.16; representing an 8% increase in the odds of SUD for each point on the pain scale) to be significantly associated with lifetime SUD in IBD (Fig. 1). Major depressive disorder was no longer associated with lifetime SUD upon adjustment for other covariates (aOR, 1.59; 95% CI, 0.69–3.67).

Upon applying the DSM-5 classification for AD, which does not include OCD or PTSD,\(^{21}\) 65 (26.3%) participants from the IBD cohort met the criteria for a SCID lifetime diagnosis of an AD. After repeating the logistic regression analysis while applying the DSM-5 definition of AD, predictors of SUD in this model were similar in magnitude and direction as those predicting SUD when we applied the DSM-IV definition of AD (see Supplementary Table 2).

**Complementary analyses**

Given that DSM-5 has replaced DSM-IV since the study was designed, we repeated our logistic regression analyses characterizing AD in a way that more closely reflects the DSM-5 concept of an AD, which does not include OCD and PTSD.\(^ {21}\) \(P\) values ≤0.05 were considered statistically significant. Analyses were performed using SPSS version 25 (IBM Corporation, Armonk, NY).

**Ethical Considerations**

The study was approved by the University of Manitoba Research Ethics Board.
Prevalence and Risk Factors of Substance Use Disorder in IBD

In the general population, those with active IBD may moderate their alcohol consumption to lessen IBD symptom exacerbation. The lifetime prevalences of drug abuse and dependence in those with IBD were similar to estimates in the American general population (abuse, 7.3% vs 7.7%; dependence, 3.6% vs 2.6%).

### TABLE 1. Participant Characteristics of Those With Inflammatory Bowel Disease and Comorbid Substance Use Disorder

| (1) All IBD | (2) IBD/no SUD | (3) IBD/SUD | P (2) vs (3) |
|-------------|----------------|-------------|--------------|
| No.         | 247 (100%)     | 206 (83.4%) | 41 (16.6%)   |          |
| Males, n (%)| 92 (37.2)      | 72 (35.0)   | 20 (48.8)    | 0.09     |
| Age, median (IQR), years | 48.1 (36.5, 59.7) | 46.9 (33.8, 59.7) | 50.5 (40.1, 58.9) | 0.25 |
| Race, n (%) | White          | Nonwhite/other |          |          |
|             | 210 (85.4)     | 178 (86.8)  | 32 (78.0)   | 0.15     |
| Income, n (%)| $<50,000     | $≥50,000    | $<50,000    | 0.88     |
|             | 58 (23.5)      | 171 (69.2)  | 58 (23.5)   |          |
| Race, n (%) | White          | Nonwhite/other |          |          |
|             | 210 (85.4)     | 178 (86.8)  | 32 (78.0)   |          |
| Education, n (%) | High school or below | Above high school |          |          |
|             | 76 (30.8)      | 171 (69.2)  | 76 (30.8)   | 0.38     |
| Decline to answer | 18 (7.3) | 17 (8.3)   | 1 (2.4)     |          |
| Marital status, n (%) | Single/divorced/separated | Married/common-law |          | 0.61     |
|             | 87 (35.2)      | 160 (64.8)  | 87 (35.2)   |          |
| IBD subtype, n (%) | Crohn’s disease | Ulcerative colitis |          | 0.90     |
|             | 153 (61.9)     | 94 (38.1)   | 153 (61.9)  |          |
| Active IBD disease, n (%) | 99 (41.3) | 80 (40.0)  | 99 (41.3)   | 0.001    |
| Age of IBD onset, n (%), years | <17 | 17–40 | >40 | 0.73|
| <17         | 32 (13)        | 164 (66.4)  | 51 (20.6)   |          |
| 17–40       | 51 (20.6)      | 142 (68.9)  | 38 (18.4)   |          |
| >40         | 73 (29.6)      | 62 (30.1)   | 26 (12.6)   | 0.73     |
| Pain Effects Scale score, median (IQR) | 11 (8, 16.3) | 11 (7, 16) | 15 (9.5, 20) | <0.0005 |
| Physical comorbidities, n (%) | 12 (4.9) | 7 (3.4)  | 5 (12.2)    | 0.02     |
| By disorder, n (%) | Panic disorder | Social phobia | Specific phobia |
|             | 72 (29.1)      | 51 (24.8)   | 11 (26.8)   | 0.68     |
|              | 32 (13)        | 22 (10.7)   | 10 (24.4)   | 0.02     |
|              | 19 (7.7)       | 12 (5.8)    | 7 (17.1)    | 0.29     |
|              | 45 (18.2)      | 34 (16.5)   | 11 (26.8)   | 0.12     |
|              | 71 (28.7)      | 59 (28.6)   | 12 (29.3)   | 0.94     |
| Any anxiety disorder, n (%) | 72 (29.1) | 51 (24.8)  | 21 (51.2)   | 0.001    |
| By disorder, n (%) | Panic disorder | Social phobia | Specific phobia |
|             | 12 (4.9)       | 7 (3.4)     | 5 (12.2)    | 0.02     |
|              | 32 (13)        | 22 (10.7)   | 10 (24.4)   | 0.02     |
|              | 19 (7.7)       | 12 (5.8)    | 7 (17.1)    | 0.01     |
|              | 24 (9.7)       | 14 (6.8)    | 10 (24.4)   | 0.001    |
|              | 11 (4.5)       | 7 (3.4)     | 4 (9.8)     | 0.07     |
|              | 12 (4.9)       | 9 (4.4)     | 3 (7.3)     | 0.42     |
|              | 13 (5.3)       | 9 (4.4)     | 4 (9.8)     | 0.16     |
| Major depressive disorder, n (%) | 98 (39.7) | 73 (35.4)  | 25 (61.0)   | 0.02     |

*At baseline visit. *n = 246. *n = 205. *n = 240. *n = 200. *n = 40. No participants met the criteria for SCID lifetime diagnosis of a general medical condition/substance-induced anxiety disorder. Bold indicates statistically significant findings (P ≤ 0.05). P values generated using χ² tests (categorical) and Student t tests (continuous).
Rates of nonmedical ever opioid use were low (n = 4, 1.6%). A 2014 study using a population-based Manitoba IBD database reported that within 10 years of IBD diagnosis, 5% were heavy opioid users. However, heavy use does not imply misuse. Possible reasons for the low prevalence of ever opioid use in the current study may be a low transition from medical to nonmedical use or a reluctance to report nonmedical use of prescription opioids.

In persons with IBD, we found that predictors of SUD were similar to those that have been previously established in the general population. On multivariable analysis, we found the factor with the strongest association with SUD was smoking history, followed by male sex, lifetime AD, and higher impact of pain. In the general population, smoking and SUD are strongly associated. A study of 34,653 Americans found individuals with alcohol abuse or dependence (64.9%) and drug abuse or dependence (75.4%) were more likely to have ever smoked than those with no lifetime psychiatric diagnosis (32.3%). Proposed mechanisms underlying the relation between SUD and smoking include behavioral and neurochemical links among substances and comorbid psychiatric disorders. Nicotine and other substances share neuronal pathways and facilitate the release of common neurotransmitters, including dopamine, norepinephrine, endogenous opioid peptides, and endocannabinoids that reward and reinforce use. Of note, we also found smoking history was associated with SUD even after adjusting for AD and MDD, suggesting comorbid AD and MDD do not fully explain the association between smoking and SUD in those with IBD.

Our finding that male sex was associated with SUD is consistent with predictors of SUD in the general population. Proposed explanations for the higher prevalence of SUD in men include sex differences in brain organization and hormonal systems, higher impulsivity and risk-taking in men, the greater stigmatization of substance use in women, and a greater tendency for women to refrain from activities that are not culturally sanctioned.

Anxiety disorders and MDD are well-established correlates of SUD in the general population. For AD, several factors have been proposed to explain this phenomenon, including self-medication of anxiety, shared vulnerability factors, and the induction of AD by substances’ toxic effects. Substance use disorder in individuals with comorbid IBD/AD warrants additional clinician attention, as comorbid AD and SUD worsens

### TABLE 2. Occurrence of Substance Use in the Study Participants (n = 247)

| Substance Use                      | n (%) |
|-----------------------------------|-------|
| Any SCID-diagnosed Lifetime SUD   | 41 (16.6) |
| Alcohol abuse                     | 23 (9.3) |
| Alcohol dependence                | 18 (7.3) |
| Drug abuse                        | 18 (7.3) |
| Drug dependence                   | 9 (3.6)  |
| Ever substance use                | 52 (21.1) |
| Cannabis                          | 48 (19.4) |
| Sedatives/hypnotics/anxiolytics    | 0      |
| Stimulants                        | 4 (1.6)  |
| Opioids                           | 4 (1.6)  |
| Cocaine                           | 7 (2.8)  |
| Hallucinogens/PCP                 | 9 (3.6)  |
| Other                             | 0      |

Abbreviations: PCP, phencyclidine.
prognosis for both AD and SUD, in general. For MDD and SUD, a systematic review and meta-analysis found a stronger association between MDD and SUD than between AD and SUD in the general population. Unexpectedly, the significant association between lifetime MDD and SUD in IBD was attenuated after adjusting for other factors. Inflammatory bowel disease may moderate the association between depression and SUD, which presents an area for future research.

Consistent with prior research that found pain frequency is associated with an elevated risk of alcohol abuse/dependence and opioid abuse/dependence, we found that elevated impact of pain in those with IBD was significantly associated with the likelihood of having an SUD in both the unadjusted and adjusted analyses. The association between higher pain impact and SUD may be explained by self-medication and the theorized potential for some substances to induce hyperalgesia and thus increase pain impact over time.

This study had many strengths. Diagnoses of AD, MDD, and SUD were established via the SCID, the gold standard for the assessment of mental disorders. Additionally, our study design allowed collection of highly detailed demographic and clinical participant characteristics. Our sample was representative of the IBD population; participants were recruited from both the community and clinics, and participant characteristics in our study were similar to those in other IBD cohorts.

We were, however, limited by the cross-sectional nature of our study, which restricted analysis of the influence of IBD clinical factors on SUD over time. Although we had assessments of symptomatic disease activity, we did not have data on the burden of disease over time, rates of surgery, frequency of hospitalization, or IBD-associated disability, which may all affect the prevalence of SUD. Our study did not seek to address rates of treatment and burden of disease of SUD in those with IBD or clinical outcomes of comorbid IBD/SUD, which represent important areas of future investigation. The DSM-5 replaced the DSM-IV after this study was designed. In the DSM-5, substance abuse (diagnosed on meeting ≥1 criterion) and dependence (threshold ≥3 criteria) disorders are combined into a single substance use disorder (≥2 criterion). This change in nosology may affect prevalence of lifetime SUD.

Since the collection of this study’s data, Canada legalized the nonmedical use of cannabis for adults. Given the high rate of nonmedical cannabis use in this study, future investigation of ever use of cannabis in the Canadian IBD population, postlegalization, is warranted. In addition, medical cannabis prescribed by a physician has been available in Canada since 2001. We did not discern in this study if nonmedical cannabis users had a history of medical cannabis use. A recent study of 201 persons with IBD found individuals using medical cannabis have characteristics associated with increased vulnerability to substance misuse when compared with those using cannabis recreationally. Persons using cannabis to treat their IBD symptoms were more likely to report using it for coping reasons (P = 0.016) and demonstrate higher levels of impulsivity (P = 0.004) and depressive symptoms (P = 0.012). Further investigations regarding the appropriate use of medical cannabis and a possible correlation to SUD in those with IBD are imperative.

In conclusion, 1 in 6 persons with IBD met the criteria for SUD. Individuals with a history of smoking, higher reported impact of pain, comorbid AD, and males were at elevated risk of SUD and could be targeted for screening of SUD in clinical practice. The substantial individual and societal burden of SUD and the prevalence of undertreatment of SUD in the general population highlight the importance of our findings and the value of subsequent investigation of SUD in those with IBD.

**SUPPLEMENTARY DATA**
Supplementary data is available at *Inflammatory Bowel Diseases* online.

**ACKNOWLEDGMENTS**
Members of the CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease are Ruth Ann Marrie, James M. Bolton, Jitender Sareen, John R. Walker, Scott B. Patten, Alexander Singer, Lisa M. Lix, Carol A. Hitchon, Renée El-Gabalawy, Alan Katz, John D. Fisk, Charles N. Bernstein, Lesley Graff, Lindsay Berrigan, Ryan Zarychanski, Christine Peschenk, James Marriot. *Deceased December 14, 2018.*

**REFERENCES**
1. Choi K, Chun J, Han K, et al. Risk of anxiety and depression in patients with inflammatory bowel disease: a nationwide, population-based study. *J Clin Med.* 2019;8:654.
2. Fuller-Thomson E, Lateef R, Sulman J. Robust association between inflammatory bowel disease and generalized anxiety disorder: findings from a nationally representative Canadian study. *Inflamm Bowel Dis.* 2015;21:2341–2348.
3. Walker JR, Ediger JP, Graff LA, et al. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. *Am J Gastroenterol.* 2008;103:1989–1997.
4. Vigod SN, Kurdvand P, Brown HK, et al. Inflammatory bowel disease and new-onset psychiatric disorders in pregnancy and post partum: a population-based cohort study. *Gut.* 2019;68:1597–1605.
5. Khassawneh M, Spence AD, Addley J, et al. The role of smoking and alcohol behaviour in the management of inflammatory bowel disease. *Best Pract Res Clin Gastroenterol.* 2017;31:553–559.
6. Mantzounakis G, Fathiora E, Saridi M. Alcohol and narcotics use in inflammatory bowel disease. *Am Gastroenterol.* 2018;31:649–658.
7. Plevinsky JM, Maddux MH, Greenley RN. Substance use in adolescents and young adults with inflammatory bowel diseases: an exploratory cluster analysis. *J Pediatr Gastroenterol Nutr.* 2019;69:324–329.
8. Wu LT, Zhu H, Ghita UE. Multicomborbid of chronic diseases and substance use disorders and their association with hospitalization: Results from electronic health records data. *Drug Alcohol Depend.* 2018;192:316–323.
9. Lai HM, Cleary M, Sitharthan T, et al. Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990-2014: a systematic review and meta-analysis. *Drug Alcohol Depend.* 2015;154:1–13.
10. Marrie RA, Graff L, Walker JW, et al. Effects of psychiatric comorbidity in immune-mediated inflammatory disease: protocol for a prospective study. *JMIR Res Protoc.* 2018;7:e15.
11. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol.* 2005;19(Suppl A):5A–36A.
12. Bernstein CN. On making the diagnosis of ulcerative colitis. *Am J Gastroenterol.* 1997;92:1247–1252.
13. Horton M, Rudick RA, Hara-Cleaver C, Marrie RA. Validation of a self-report comorbidity questionnaire for multiple sclerosis. *Neuroepidemiology*. 2010;35:83–90.

14. Ritvo P, Fischer J, Miller D, et al. *Multiple Sclerosis Quality of Life Inventory: A User’s Manual*. New York, NY: National MS Society; 1997.

15. Stewart A, Ware J. *Measuring Functioning and Well-Being: The Medical Outcomes Study Approach*. Durham: Duke University Press; 1992.

16. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. *Scand J Gastroenterol*. 1978;13:833–837.

17. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. *Lancet*. 1980;1:514.

18. Kao LT, Lin HC, Lee HC. Inflammatory bowel disease and bipolar disorder: A population-based cross-sectional study. *J Affect Disord*. 2019;247:120–124.

19. Marrie RA, Walld R, Bolton JM, et al.; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease. Increased incidence of psychiatric disorders in immune-mediated inflammatory disease. *J Psychosom Res*. 2017;101:17–23.

20. Edlund MJ, Sullivan MD, Han X, et al. Days with pain and substance use disorders: is there an association? *Clin J Pain*. 2013;29:689–695.

21. Hasin DS, Stinson FS, Ogburn E, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry*. 2007;64:830–842.

22. Compton WM, Thomas YF, Stinson FS, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. *Arch Gen Psychiatry*. 2007;64:566–576.

23. Kupfer DJ. Anxiety and DSM-5. *Dialogues Clin Neurosci*. 2015;17:245–246.

24. Targownik LE, Nugent Z, Singh H, et al. The prevalence and predictors of opioid use in inflammatory bowel disease: a population-based analysis. *Am J Gastroenterol*. 2014;109:1613–1620.

25. Weinberger AH, Funk AP, Goodwin RD. A review of epidemiologic research on smoking behavior among persons with alcohol and illicit substance use disorders. *Prev Med*. 2016;92:148–159.

26. Smith PH, Mazure CM, McKee SA. Smoking and mental illness in the US population. *Tob Control*. 2014;23:e147–e153.

27. Kalman D, Morissette SB, George TP. Co-morbidity of smoking with psychiatric and substance use disorders. *Am J Addict*. 2005;14:106–123.

28. Fattore L, Melis M, Fadda P, et al. Sex differences in addictive disorders. *Front Neuroendocrinol*. 2014;35:272–284.

29. Becker JB, Perry AN, Westenbroek C. Sex differences in the neural mechanisms mediating addiction: a new synthesis and hypothesis. * Biol Sex Differ*. 2012;3:14.

30. McHugh RK, Votaw VR, Sugarman DE, et al. Sex and gender differences in substance use disorders. *Clin Psychol Rev*. 2018;66:12–23.

31. Robinson J, Sareen J, Cox BJ, et al. Role of self-medication in the development of comorbid anxiety and substance use disorders: a longitudinal investigation. *Arch Gen Psychiatry*. 2011;68:800–807.

32. Turner S, Motis N, Bolton J, et al. Self-medication with alcohol or drugs for mood and anxiety disorders: a narrative review of the epidemiological literature. *Depress Anxiety*. 2018;35:851–860.

33. Vorspan F, Mehtelli W, Dupuy G, et al. Anxiety and substance use disorders: co-occurrence and clinical issues. *Curr Psychiatry Rep*. 2015;17:4.

34. Pasche S. Exploring the comorbidity of anxiety and substance use disorders. *Curr Psychiatry Rep*. 2012;14:176–181.

35. McHugh RK. Treatment of co-occurring anxiety disorders and substance use disorders. *Harv Rev Psychiatry*. 2015;23:99–111.

36. Hasin DS, O’Brien CP, Auriacombe M, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. *Am J Psychiatry*. 2013;170:834–851.

37. Cox C. The Canadian Cannabis Act legalizes and regulates recreational cannabis use in 2018. *Health Policy*. 2018;122:205–209.

38. Hansen TM, Sabourin BC, Oketola B, et al. Cannabis use in persons with inflammatory bowel disease and vulnerability to substance misuse. *Inflamm Bowel Dis*. 2019. [Epub ahead of print].

39. Olfson M, Blanco C, Wall MM, et al. Treatment of common mental disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions-III. *J Clin Psychiatry*. 2019;80:18m12352.